2nd ANNUAL NETWORK MEETING
WEDNESDAY 20 MARCH 2019
Edgbaston Park Hotel & Conference Centre, University of Birmingham

09.00 Registration and refreshments

09.15 Welcome/Network information
Chair: Professor Cal MacLennan

09.30 Opening Address
Professor Sir Brian Greenwood
Manson Professor of Tropical Medicine, London School of Hygiene and Tropical Medicine, UK
Chair - BactiVac Network Advisory Board

09.45 MRC / BBSRC
Dr Martin Broadstock, Programme Manager, Medical Research Council, UK
Dr Ceri-Wyn Thomas, Strategy and Policy Manager, Biotechnology & Biological Sciences Research Council, UK

10.10 Making quality vaccines for Lower and Middle Income Countries
Professor Gordon Dougan
GSK Professor of Molecular Microbiology, The Department of Medicine, Cambridge University, UK

10.40 Refreshments

11.00 Role of developing country vaccine manufacturers in global vaccine supply
Dr Satish Ravetkar
Executive Director, Serum Institute of India Pvt Ltd, India

11.45 The challenge of bacterial vaccines for global health
Dr Jerome Kim
Director General, The International Vaccine Institute (IVI), Republic of Korea

12.15 Lunch

13.15 Livestock vaccines. Leading or lagging?
Professor Rick Titball
Professor of Molecular Microbiology, University of Exeter, UK
Chair: Dr Ted Fjällman

13.45 Catalyst funding awards round 1 – project presentations: refer to page 2

14.45 Refreshments

15.15 Group photograph
Chair: Dr Jo Dean

15.30 Speed dating session

16.45 Close of day programme

18.30 Conference dinner
This will be held in The Fry Room, Edgbaston Park Hotel & Conference Centre, B15 2RS

The programme is subject to change
<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Post Held</th>
<th>Institution</th>
<th>Project Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.45</td>
<td>Dr Roma Chilengi</td>
<td>Chief Scientific Officer</td>
<td>Centre for Infectious Disease Research in Zambia (Zambia)</td>
<td>Measurement of <em>Shigella</em>-specific antibodies in the first two years of life in Zambian children to refine correlates of protection and determine the optimal window for vaccination</td>
</tr>
<tr>
<td>13.50</td>
<td>Dr Sean Elias</td>
<td>Post-Doctoral Scientist</td>
<td>University of Oxford, UK</td>
<td>Measuring non-typhoidal Salmonella specific antibodies in oral fluid as a non-invasive alternative to serum.</td>
</tr>
<tr>
<td>13.55</td>
<td>Dr Boris Gavrilov</td>
<td>Director Biologics Development Facility</td>
<td>Huvepharma, Bulgaria</td>
<td>Supporting the development of a DIVA compatible glycoconjugate vaccine for brucellosis</td>
</tr>
<tr>
<td>14.00</td>
<td>Dr Michael Jarvis</td>
<td>Associate Professor</td>
<td>The Vaccine Group Ltd (TVG) Ltd</td>
<td>Attenuated herpesvirus-based vaccines for low-cost antibiotic-independent control of bacterial disease in livestock - a proof of concept study</td>
</tr>
<tr>
<td>14.05</td>
<td>Prof Constantino Lopez-Macias</td>
<td>Principal Investigator</td>
<td>Mexican Social Security Institute, Mexico</td>
<td>Improving the production of a multivalent experimental vaccine against the diseases induced by <em>Salmonella enterica</em></td>
</tr>
<tr>
<td>14.10</td>
<td>Dr Pietro Mastroeni</td>
<td>Reader in Infection and Immunity</td>
<td>University of Cambridge, UK</td>
<td>Using General Modules for Membrane Antigens (GMMA) as multivalent <em>Salmonella</em> vaccines for Low-Middle Income Countries (LMIC) and travellers</td>
</tr>
<tr>
<td>14.15</td>
<td>Dr Esther Muthumbi</td>
<td>PhD Student, Research Medical Officer</td>
<td>KEMRI-Wellcome, Kenya</td>
<td>Using seroepidemiology of non-Typhoidal Salmonella (NTS) in Kenya to understand changes in risks of invasion and transmission and direct the clinical development programme for vaccines against NTS</td>
</tr>
<tr>
<td>14.20</td>
<td>Dr Arlo Randall</td>
<td>Director of Bioinformatics</td>
<td>Antigen Discovery, Inc, USA</td>
<td>Protein antibody markers of pneumococcal carriage in support of protein and whole cell vaccine trial design using panproteomic antibody screening</td>
</tr>
<tr>
<td>14.25</td>
<td>Dr Christine Rollier</td>
<td>Research Scientist</td>
<td>University of Oxford, UK</td>
<td>A novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections: preclinical proof of concept</td>
</tr>
<tr>
<td>14.30</td>
<td>Mr Michelo Simuyandi</td>
<td>Research Fellow</td>
<td>Centre for Infectious Disease Research in Zambia (Zambia)</td>
<td>Field evaluation and validation of a novel and rapid ETEC diagnostic assay in a resource limited setting</td>
</tr>
<tr>
<td>14.35</td>
<td>Dr Carla Solorzano Gonzalez</td>
<td>Post-Doctoral Researcher</td>
<td>Liverpool School of Tropical Medicine, UK</td>
<td>Identification of correlates of protection against pneumococcal colonization</td>
</tr>
</tbody>
</table>
PROGRAMME – DAY TWO  THURSDAY 21 MARCH 2019  2nd ANNUAL NETWORK MEETING

08.30  Registration  
Chair:  Professor Richard Adegbola

09.00  Vaccines, an achievement of civilization and health insurance for the future  
**Dr Rino Rappuoli**  
Chief Scientist & Head of External Research and Development at GlaxoSmithKline Vaccines, Italy

09.30  Recombinant glycoconjugate vaccines  
**Professor Brendan Wren**  
Professor of Microbial Pathogenesis, London School of Hygiene and Tropical Medicine, UK

10.00  Wellcome: Vaccine strategies and initiatives  
**Shobana Balasingam**  
Programme Officer, Wellcome Trust, UK

10.30  Gonococcal vaccine preferred product characteristics and public health value proposition: Initial global stakeholder consultation  
**Catalyst funding award round 1 – project report**  
**Dr Sami Gottlieb**, Medical Officer, World Health Organisation (Switzerland)

11.00  Discussion & refreshments  
Advancing global health vaccines: pitfalls and obstacles

11.50  Feedback from group discussions

12.40  Lunch  
Chair:  Professor Adam Cunningham

13.30  Optimising existing vaccines  
**Dr Alex Richter**  
Consultant in Clinical Immunology, University of Birmingham, UK

14.00  Immunity to enteric bacterial pathogens  
**Dr Marcela F Pasetti**  
Professor of Microbiology and Immunity, University of Maryland, USA

14.30  Bacterial vaccine development: A research and development perspective  
**Dr Annaliesa S Anderson**  
Vice President & Chief Scientific Officer for Bacterial Research, Pfizer Inc, USA

15.00  Refreshments

15.30  Vaccine development in SMEs - the drivers behind early commercialisation  
**Dr Ted Fjällman**  
Chief Executive Officer, Prokarium Ltd, UK

16.00  GAS vaccines: WHO preferred product characteristics and R&D technical roadmap  
**Dr Johan Vekemans**  
Medical Officer, World Health Organisation, Switzerland

16.30  Closing remarks – BactiVac Directors  
**Professor Calman MacLennan & Professor Adam Cunningham**

16.45  Close of conference